Essential insights into HIV-1 latency mechanisms
HIV-Tocky, a new viral reporter system, uncovers the molecular mechanisms of provirus silencing and expression.
List view / Grid view
HIV-Tocky, a new viral reporter system, uncovers the molecular mechanisms of provirus silencing and expression.
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
The algorithm can accurately diagnose cases of lung adenocarcinoma, determining structural features that are statistically most significant for assessing disease severity and likelihood of tumour recurrence.
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
A new study reveals that pain management could be greatly improved by considering patient sex as fundamental.
Researchers found, using human respiratory epithelium organoids, that P. aeruginosa breaches respiratory epithelia by goblet cell invasion.
The development of a new membrane which better mimics human extracellular membranes will enable more accurate disease research.
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
The future of liquid biopsy is poised to revolutionise medical diagnostics and treatment. Explore the latest advancements and future prospects of liquid biopsy in our comprehensive eBook.
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a…
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
In this Q&A, Pascaline Lécorché, Head of Chemical Biology at Vect-Horus, outlines the potential of RNA interference therapeutics and the challenges of their use in vivo. There are several strategies to overcome these, and why peptide-based vectors targeting the LDL receptor are a promising approach.